Table 1 Clinical, radiological and molecular characteristics of the study population.
From: Multimodal integrated approaches in low grade glioma surgery
Parameter | Value |
|---|---|
No. of patients | 288 |
Age | 37.5 years (18–74) |
Sex | |
Male | 168 (58.33) |
Female | 120 (41.67) |
Clinical onset | |
Generalized seizure | 160 (55.56) |
Focal seizure | 80 (27.78) |
Incidental | 36 (12.5) |
Others (neurological deficits, mood changes) | 12 (4.17) |
Tumor side | |
Left | 160 (55.56) |
Right | 128 (44.44) |
Tumor site | |
Frontal (inferior frontal gyrus, premotor cortex, middle frontal gyrus, Broca’s area) | 118 (40.97) |
Parietal | 34 (11.81) |
Temporal | 54 (18.75) |
Insular | 77 (26.74) |
Occipital | 5 (1.74) |
Preoperative tumoral volume on T2WI (cm3) | 40 (22–68) |
Preoperative ΔT2T1 MRI index, cm3 | |
ΔT2T1 MRI index | 10 (0–20) |
≥ 15 | 116 (40.38) |
< 15 | 172 (59.72) |
Anesthesia | |
Awake | 175 (60.77) |
General | 113 (39.23) |
Intraoperative surgical protocol | |
Protocol 1 | 77 (26.74) |
Protocol 2 | 137 (47.57) |
Protocol 3 | 74 (25.69) |
EOR % | |
≥ 90 | 146 (50.69) |
70–89 | 101 (35.07) |
< 70 | 41 (14.24) |
Median EOR % | 90 (28–100) |
Protocol 1: Median EOR % | 83 (28–100) |
Protocol 2: Median EOR % | 88 (34–100) |
Protocol 3: Median EOR % | 100 (50–100) |
Awake surgery | 90 (28–100) |
General anesthesia | 85 (34–100) |
Median EOR % in awake surgery subgroup | |
Protocol 1, only awake surgery: Median EOR % | 85 (28–100) |
Protocol 2, only awake surgery: Median EOR % | 90 (49–100) |
Protocol 3, only awake surgery: Median EOR % | 100 (50–100) |
Median EOR % stratified by molecular class | |
DA IDH 1/2wt | 83 (34–100) |
DA IDH 1/2mt | 87 (28–100) |
OD IDH 1/2mt,1p19q cod | 92 (55–100) |
Post-operative residual tumor volume on T2WI (cm3) | |
< 10 | 189 (65.63) |
10–19 | 51 (17.71) |
20–29 | 23 (7.99) |
≥ 30 | 25 (8.68) |
Median | 5 (0–125) |
Diagnosis WHO 2016 | |
DA IDH-wt | 34 (11.8) |
DA IDH-mt | 163 (56.6) |
OD IDH-mt 1p19q cod | 91 (31.6) |
Clinical follow up | |
Median follow up (months) | 71 (18–239) |
Patient deaths | 141 (48.96) |
n° w/disease progression | 199 (69.1) |
Median time to progression (months) | 46 (4–194) |
n° w/malignant progression | 159 (55.21) |
Median time to malignant progression (months) | 60 (6–239) |
